Software

Powerful tools for innovative, faster clinical trials

Transform trial design with industry-leading software built to optimize every phase of development. From adaptive trial design to financial forecasting, Berry's suite of tools empowers teams to design Innovative trials, reduce risk, and accelerate time to market. Discover how FACTS, ADDPLAN, and QUOTES give you the clarity, precision, and confidence to make better decisions - every step of the way.

Biological structures and spirals.

Find the right tool for innovative trial design

Facts logo

Innovative designs, faster decisions

The fastest, most versatile tool on the market for fixed and adaptive clinical trial design - plan, simulate, evaluate, and analyze innovative trials that meet the unique goals of a clinical development program at any phase.

ADDPLAN logo

Innovative designs, faster decisions

Proven software for designing and analyzing classical clinical trials across Phases 1 to 4 - trusted by regulators, pharma, and academics worldwide.

Quotes logo

Innovative designs, faster decisions

Bridge the gap between clinical and financial. Use clinical trial simulation to optimize ROI and expected NPV to make smart drug development decisions.

FACTS (Fixed and Adaptive Clinical Trial Simulator) is the industry’s most powerful tool for designing, simulating, and analyzing adaptive clinical trials. With capabilities spanning from phase 1 dose escalation trials to adaptive platform trial designs - FACTS helps teams design custom trials to fit their unique clinical goals.

Key Features

  • Flexible design capabilities: FACTS provides the building blocks for you to combine many adaptations in a single trial across a wide range of trial types (dose escalation, dose selection, adaptive phase 3, seamless phase 2/3, enrichment designs, and platform trials).
  • Data-Driven Decision-Making: Biostatisticians prioritize evidence-based design choices, and FACTS provides simulation-backed insights that evaluate a trial's behavior, help understand uncertainty, and strengthen regulatory submissions.
  • Powerful statistics: FACTS brings innovative statistical methods right to user's fingertips. Bayesian models, response adaptive randomization, multiple imputation, and dose response models that all work together.

ADDPLAN (ADaptive Design PLANner) is trusted software for planning many types of adaptive clinical trials. Spanning Phases 1 to 4, it supports Multiple Comparison Procedures (MCP), Population Enrichment, and Dose Finding (MCP-Mod). Used by regulatory agencies, top pharma, and researchers, ADDPLAN enables smarter, faster, and more precise trial designs with a user-friendly interface.

Key Features

  • Simulation & Analysis Capabilities: Simulate trial outcomes, test scenarios, and calculate sample sizes to make smarter, data-driven decisions before trials begin.
  • Multi-arm group sequential designs: Find success and futility stopping bounds for multiple arm, multiple stage (MAMS) adaptive designs.
  • MCP-Mod Dose-Finding Design: The first commercial implementation of MCP-Mod, which is endorsed by the FDA and EMA, enabling precise dose selection to reduce risk and improve regulatory success.

QUOTES (Quantification and Optimization of Trial Expectations Simulator) helps program development teams estimate the financial impact of trial design decisions. By simulating Phase 2 and Phase 3 trial outcomes, QUOTES calculates expected Net Present Value (eNPV) and Return on Investment (ROI), enabling innovative, data-driven strategy. With the ability to model trial size, design, and go/no-go decisions, QUOTES helps teams reduce risk, shorten timelines, and maximize financial returns. In addition, QUOTES facilitates communication about clinical trial efficiencies between trial design statisticians and financially minded executives.

Key Features

  • eNPV & ROI Estimation: Forecasts Net Present Value (eNPV) and Return on Investment (ROI) to quantify financial impact and optimize development strategies.
  • Weigh program costs: like early phase trials, sample size, time to approval, and site onboarding against potential profit of approved products to estimate economic expectations of different simulation assumptions.